Treatment and Drug Development Approach for Cystic Fibrosis Cited as Model for Rare Diseases
BETHESDA, Md., Oct. 15, 2013 /PRNewswire-USNewswire/ -- In the largest meeting of its kind, nearly 4,000 doctors, scientists and caregivers from around the world will meet in Salt Lake City from Oct. 17 through Oct. 19 to present the latest advancements in cystic fibrosis drug development, research and care.
Highlighted topics of the 27th annual North American Cystic Fibrosis Conference (NACFC) include:
- Emerging therapies that target the underlying genetic defect in CF
- Drug discovery and development programs designed to address all CF gene mutations
- Early detection and treatment of CF-related diabetes
- Meeting the needs of the growing adult CF population
- Open-label data on a breakthrough CF drug approved by the FDA in 2012
Organized by the Cystic Fibrosis Foundation, NACFC takes place at a time of dramatic advances in treatment for cystic fibrosis and the health of those with the disease. The life expectancy of a child with CF has doubled in the last 30 years, and research to find a cure is more promising than ever before.
Cystic fibrosis is a fatal genetic disease that causes life-threatening lung infections, lung destruction and premature death. It affects about 30,000 people in the U.S. and 70,000 worldwide.
- The 27th Annual North American Cystic Fibrosis Conference, the largest international gathering of cystic fibrosis research scientists, clinicians and caregivers
When & Where:
- Thursday, Oct. 17 – Saturday, Oct. 19, 2013
- Salt Palace Convention Center, Salt Lake City, Utah
About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more cystic fibrosis research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The Cystic Fibrosis Foundation is a donor-supported nonprofit organization. For more information, go to www.cff.org.
SOURCE Cystic Fibrosis Foundation